Current product identity
Wegovy coverage now requires an injection-or-tablet check
The current Novo Nordisk DailyMed label was updated June 18, 2026 and includes Wegovy subcutaneous injections and once-daily tablets. Both presentations have adult weight-management and cardiovascular-risk-reduction label contexts, but the injection label also includes adolescents age 12 and older with obesity and adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced liver fibrosis. The MASH indication uses accelerated-approval language. A coverage request should identify the exact presentation and actual diagnosis rather than treating every Wegovy claim as the same product request.
- Confirm branded Wegovy, semaglutide as the active ingredient, injection or tablet route, prescription details, patient age, diagnosis, and current label context.
- Do not describe Wegovy as injection-only, assume an injection authorization transfers to tablets, or apply the adult tablet indication to an adolescent.
- Do not transfer an injection-specific MASH or pediatric indication to tablets, and do not present accelerated approval as proof that every plan must cover the product.
What the plan may be asking for
Prior authorization, exclusions, step therapy, and claim errors need different responses
HealthCare.gov defines prior authorization as approval a health plan may require before a service or prescription is covered. A Wegovy request may instead be delayed by missing information, an indication or age criterion, step therapy, a weight-management-drug exclusion, a non-formulary rule, a quantity limit, a refill-timing rule, a preferred-pharmacy requirement, an exact-formulation mismatch, or a processing error. The current policy or written notice should identify the issue; an old form or social-media checklist cannot.
- Ask for the policy name, effective date, exact formulation or National Drug Code when available, required records, submission route, case number, deadline, and appeal instructions.
- Confirm whether the request is under a pharmacy or medical benefit and whether the plan is evaluating weight management, cardiovascular risk reduction, MASH, or another actual diagnosis.
- Do not assume every plan requires the same BMI, comorbidity, lifestyle record, prior medication, treatment duration, or response threshold.
Accurate documentation
Match real records to the actual labeled-use and plan criterion
Depending on the request, a plan may ask for current and historical weight, height and BMI, a weight-related condition, established cardiovascular disease, relevant liver evaluation, prior treatment, pharmacy records, response, adverse effects, contraindications, or clinician notes. The useful record is the patient’s real history with dates and supporting documents. A treatment that failed, was not tolerated, was contraindicated, was unavailable, or was never prescribed must not be described as the same event.
- Keep the plan notice, current medication list, weight and BMI records, relevant diagnoses, prior prescriptions, pharmacy history, adverse-effect notes, and clinician rationale together.
- For a cardiovascular or MASH request, use the responsible clinician’s documented diagnosis and supporting evaluation rather than a patient-written label or self-diagnosis.
- Never alter a BMI, invent a comorbidity or prior treatment, reuse another patient’s appeal language, or select an indication only because it appears easier to cover.
Corrections, exceptions, and appeals
Use the written denial reason and the plan’s own process
Missing information may support a corrected or resubmitted request, while a clinical or formulary rule may lead the prescriber to consider an exception or appeal when the facts support it. Commercial, employer, Marketplace, Medicaid, and Medicare plans can use different forms, deadlines, benefits, and review standards. CMS describes a specific Medicare Part D formulary-exception process that requires a prescriber supporting statement; that process should not be copied as a universal rule for every plan or every Wegovy indication.
- Ask whether the next action is a corrected claim, added documentation, resubmitted prior authorization, formulary exception, internal appeal, expedited review, external review, or a different prescription.
- Have the prescriber explain real contraindications, adverse effects, prior response, and clinical reasoning instead of relying on a copied medical-necessity template.
- A prescription, resubmission, appeal, clinician statement, savings offer, or telehealth enrollment does not guarantee coverage or pharmacy payment.
Clinical safety remains separate
Coverage approval does not decide whether Wegovy is appropriate
Even when coverage is approved, the prescriber still needs to determine whether the exact Wegovy presentation fits the patient. The current label includes formulation-specific administration, contraindications, warnings, adverse effects, interaction considerations, and switching instructions. Other semaglutide products, GLP-1 medicines, insulin or sulfonylureas, gastrointestinal symptoms, dehydration, kidney or gallbladder concerns, diabetic eye disease, pregnancy plans, procedures, and prior reactions can change the clinical plan.
- Share every prescription, over-the-counter medicine, supplement, glucose-lowering medicine, current symptom, and upcoming procedure with the responsible clinicians.
- Do not start, stop, overlap, split, substitute, convert, or switch Wegovy injections, Wegovy tablets, Ozempic, Rybelsus, or compounded semaglutide because coverage changed.
- Use urgent care rather than insurance messaging for severe abdominal pain, repeated vomiting, severe dehydration, fainting, serious allergy symptoms, confusion, or another emergency pattern.
Safer alternatives to coverage shortcuts
A denial does not make compounded semaglutide generic Wegovy
If Wegovy coverage remains unavailable, a licensed clinician can review whether another labeled medicine, cash-pay branded access, non-drug care, or a patient-specific compounded prescription is clinically and legally appropriate. Compounded semaglutide is not an FDA-approved finished drug product, is not Wegovy, and should not be represented as a covered generic equivalent. Peptide12 lists clinician-reviewed Wegovy and semaglutide pathways, but eligibility, prescribing, insurance approval, pharmacy dispensing, and cost are never guaranteed.
- Compare medication identity, clinician review, pharmacy dispensing, route-specific supplies, shipping, follow-up, refill support, adverse-event support, and cancellation terms—not only an advertised monthly price.
- Verify prescriber licensure, pharmacy identity, exact product, active ingredient, route, label, storage, expiration or beyond-use date, and total cost before paying.
- Avoid no-prescription checkout, research-use semaglutide sold for human treatment, hidden pharmacies, guaranteed authorization, copied dose instructions, and compounded products called FDA approved or generic Wegovy.